With the discovery of a new treatment for stage 2 hypertension that keeps people from losing their appetite, Pfizer is again looking for new ways to tackle the problem.
The drug has been approved in the United States, and it has been used to treat patients with the rare disease, known as stage 2, hypertension, for years.
But in recent years, Pfizers CEO James Allyn has pushed to find a way to lower the risk of death from the disease.
Pfizer is developing an oral form of its drug that could potentially reduce the risk for some people to develop stage 2 as well as other serious cardiovascular problems, the company said.
The company plans to launch a commercial version of the drug in the next six to eight months.
“Our first step is to find an effective treatment, and we’re currently evaluating more than a dozen treatments for hypertension, including oral and topical treatments, which can potentially be taken on a regular basis,” Allyn said at a conference Tuesday.
The new Pfizer drug, known in the U.S. as TNF-alpha, will be made by AstraZeneca.
The company has been testing the drug for several years, and Pfizer has also been working with the American Diabetes Association to develop a drug that lowers the risk.
Pfizer says the drug could save the lives of up to 1,200 Americans a year.
AstraZenecal says the new Pfizers drug, called TNFalpha, has been shown to be effective at lowering the risk associated with the disease in a trial that started in the spring.
The drug’s mechanism of action, however, has not yet been determined, and its safety has not been proven in large, long-term studies, Astra Zeneca said.
The American Diabetes Society says it is monitoring the new TNF alpha drug.
Pfizers says TNF Alpha could be “one of the safest, most effective and most effective antihypertensive drugs in the world.”
I know it has its limitations, but it’s a huge step forward in treating hypertension and it will be a big step forward for the American diabetes community, said Andrew Sacks, chief executive of the American Heart Association.
The American Heart Foundation says TNAB is a significant breakthrough in treatment and will help reduce the incidence of death and disability among people with hypertension.
“The drug is an important step in our fight against hypertension,” said Dr. Mark L. Pritchard, president and CEO of the Heart Foundation.
Pritchard said it will take a while to see if TNFAlpha has the potential to reduce deaths and disability, but he is confident it will.
The new drug could be available by 2021, he said.TNFalpha is a type of blood clotting factor found in blood vessels and that triggers a cascade of reactions that include a reduction in blood pressure, increased heart rate, and increased heart rhythm.
It can also lead to bleeding, stroke and death.
The disease, which affects the heart and blood vessels, is the most common in the elderly.
About 15 million Americans have stage 2 of hypertension, according to the U;A.
The risk for people in the middle age group is nearly 20%.
Pritchers comments came as the pharmaceutical industry has been working to develop drugs that are less harmful than existing drugs.
The goal is to keep drugs from killing people in clinical trials, or getting approval for use.
Pritzker, the drugmaker’s former CEO, is expected to retire at the end of the year.